Pharmicell파미셀

Pharmicell's trailing profits are high relative to its history, but the share price has fallen sharply over the past year.

Pharmicell, a Korean biopharma and fine chemicals maker, reported trailing twelve-month revenue of ₩135.9B and operating income of ₩44.1B as of H1 2026, a much stronger picture than in earlier years. The share price closed at ₩10,180 on 2026-10-22, down 24% over one year and 19% over one month, and roughly half its 52-week high. The data does not give a clear reason for the drop.

What stands out

• Revenue for 2025 was ₩114.1B, up 75.9% from 2024, and operating margin rose to 30.1% from 7.2%.
• Trailing operating margin is 32.4% and free cash flow is ₩26.1B, while borrowings of ₩25.0B exceed cash of ₩15.0B.
• The fair value model's base estimate is ₩5,623 per share, below the current price of ₩10,180; bear and bull cases are ₩3,583 and ₩8,881.
• Foreign ownership fell from 11.4% to 8.6% over about 60 days, and foreign investors were net sellers over the last 20 trading days.
• Recent filings include a major sales or supply contract on 2026-10-14 and 2026-08-07, plus an investor relations event and several 5%+ holding reports. No recent news headlines were provided.

What to watch

• The next half-year or annual results and whether margins hold near the trailing levels.
• Details of the recent supply contracts and any further large holding changes or insider filings.
• Foreign and institutional selling in the coming weeks, given the reduced foreign ownership.